# Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed

Source: https://onco.cc/trials/nct07476287/  
OnCo record `nct07476287` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of PF-08634404 in small-cell lung cancer, run by Pfizer, now recruiting.

## Summary

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07476287 by Pfizer, with 40 participants planned, started 2026-07-02 and due to reach its primary completion in 2028-03-19. Interventions recorded: PF-08634404, Chemotherapy. Conditions listed: Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07476287
- Phase: 2
- Setting: A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER
- Sponsor: Pfizer
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07476287: https://clinicaltrials.gov/study/NCT07476287

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [PF-08634404](https://onco.cc/drugs/pf-08634404/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct07476287.json